다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Molecules a journal of synthetic chemistry and natural product chemistry, v.25 no.8, 2020년, pp.1834 -
Lentini, Giovanni (Department of Pharmacy–) , Cavalluzzi, Maria Maddalena (Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona, 4, I-70126 Bari, Italy) , Habtemariam, Solomon (mariamaddalena.cavalluzzi@uniba.it)
AI-Helper
The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona ...
1. Sweiti H. Ekwunife O. Jaschinski T. Lhachimi S.K. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review Curr. Res. Clin. Exp. 2017 84 10 21 10.1016/j.curtheres.2017.01.007
2. Habtemariam S. Lentini G. Did ebola survivors use plant medicines, and if so, which ones? Phytother. Res. 2015 29 632 10.1002/ptr.5279 25640112
3. Patane S. Ebola: Is there a hope from treatment with cardiovascular drugs? Int. J. Cardiol. 2014 177 524 526 10.1016/j.ijcard.2014.08.114 25205490
4. Lentini G. Habtemariam S. Ebola therapy: Developing new drugs or repurposing old ones? Int. J. Cardiol. 2015 179 325 10.1016/j.ijcard.2014.11.092 25464477
5. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Drug. Dev. Res. 2020 10.1002/ddr.21656
6. Luo H. Tang Q. Shang Y. Liang S. Yang M. Robinson N. Liu J. Can chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs Chin. J. Integr. Med. 2020 10.1007/s11655-020-3192-6
7. Coatney G.R. Pitfalls in a discovery: The chronicle of chloroquine Am. J. Trop. Med. Hyg. 1963 12 121 128 10.4269/ajtmh.1963.12.121 14021822
8. Gao J. Tian Z. Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Biosci. Trends 2020 14 72 73 10.5582/bst.2020.01047 32074550
9. Wang M. Cao R. Zhang L. Yang X. Liu J. Xu M. Shi Z. Hu Z. Zhong W. Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 2020 30 269 271 10.1038/s41422-020-0282-0 32020029
10. Touret F. de Lamballerie X. Of chloroquine and COVID-19 Antivir. Res. 2020 177 104762 10.1016/j.antiviral.2020.104762 32147496
11. Calain P. The Ebola clinical trials: A precedent for research ethics in disasters J. Med. Ethics 2018 44 3 8 10.1136/medethics-2016-103474 27573153
12. Shah S.K. Wendler D. Danis M. Examining the ethics of clinical use of unproven interventions outside of clinical trials during the Ebola epidemic Am. J. Bioeth. 2015 15 11 16 10.1080/15265161.2015.1010996 25856592
13. Frisk-Holmberg M. Bergqvist Y. Englund U. Chloroquine intoxication Br. J. Clin. Pharm. 1983 15 502 503 10.1111/j.1365-2125.1983.tb01540.x 6849790
14. Laing R. Waning B. Gray A. Ford N. ’t Hoen E. 25 years of the WHO essential medicines lists: Progress and challenges Lancet 2003 361 1723 1729 10.1016/S0140-6736(03)13375-2 12767751
15. Crumb W.J. Vicente J. Johannesen L. Strauss D.G. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel J. Pharm. Toxicol. Meth. 2016 81 251 262 10.1016/j.vascn.2016.03.009
16. Rodriguez-Menchaca A.A. Navarro-Polanco R.A. Ferrer-Villada T. Rupp J. Sachse F.B. Tristani-Firouzi M. Sanchez-Chapula J.A. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel Proc. Natl. Acad. Sci. USA 2008 105 1364 1368 10.1073/pnas.0708153105 18216262
17. Mzayek F. Deng H. Mather F.J. Wasilevich E.C. Liu H. Hadi C.M. Chansolme D.H. Murphy H.A. Melek B.H. Tenaglia A.N. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers PLoS Clin. Trials 2007 2 e6 10.1371/journal.pctr.0020006 17213921
18. Riou B. Barriot P. Rimailho A. Baud F.J. Treatment of severe chloroquine poisoning N. Engl. J. Med. 1988 318 1 6 10.1056/NEJM198801073180101 3336379
19. McConathy J. Owens M.J. Stereochemistry in drug action Prim. Care Companion J. Clin. Psychiatry 2003 5 70 73 10.4088/PCC.v05n0202 15156233
20. Tucker G.T. Chiral switches Lancet 2000 355 1085 1087 10.1016/S0140-6736(00)02047-X 10744105
21. Polak S. Winiowska B. Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs’ cardiotoxic properties J. Appl. Toxicol. 2009 29 183 206 10.1002/jat.1395 18988205
22. Sanchez-Chapula J.A. Navarro-Polanco R.A. Culberson C. Chen J. Sanguinetti M.C. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block J. Biol. Chem. 2002 277 23587 23595 10.1074/jbc.M200448200 11960982
23. Thai K.-M. Ecker G.F. Predictive models for HERG channel blockers: Ligand-based and structure-based approaches Curr. Med. Chem. 2007 14 3003 3026 10.2174/092986707782794087 18220737
24. Ofori-Adjei D. Ericsson O. Lindstrom B. Sjoqvist F. Protein binding of chloroquine enantiomers and desethylchloroquine Br. J. Clin. Pharm. 1986 22 356 358 10.1111/j.1365-2125.1986.tb02900.x
25. Haberkorn A. Kraft H.P. Blaschke G. Antimalarial activity of the optical isomers of chloroquine diphosphate Trop. Parasitol. 1979 30 308 312
26. Ng M.-L. Tan S.-H. See E.-E. Ooi E.-E. Ling A.-E. Proliferative growth of SARS coronavirus in Vero E6 cells J. Gen. Virol. 2003 84 (Pt 12) 3291 3303 10.1099/vir.0.19505-0 14645910
27. Vincent M.J. Bergeron E. Benjannet S. Erickson B.R. Rollin P.E. Ksiazek T.G. Seidah N.G. Nichol S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Virol. J. 2005 2 69 10.1186/1743-422X-2-69 16115318
28. Craiga J.C. Ansari A.M. Resolution of 7-chloro-4(4′-diethylamino-1′methylbutyl)aminoquinoline (chloroquine) into its enantiomers Chirality 1993 5 188 190 10.1002/chir.530050315
29. Sinha M. Dola V.R. Soni A. Agarwal P. Srivastava K. Haq W. Puri S.K. Katti S.B. Synthesis of chiral chloroquine and its analogues as antimalarial agents Bioorg. Med. Chem. 2014 22 5950 5960 10.1016/j.bmc.2014.09.009 25284252
30. Lentini G. Shouldn’t enantiomeric purity be included in the “minimum information about a bioactive entity”? Nat. Rev. Drug Discov. 2012 11 730 10.1038/nrd3503-c1 22935805
31. Cavalluzzi M.M. Lovece A. Bruno C. Franchini C. Lentini G. Preparation of (？)-( R )-2-(2,3,4,5,6-pentafluorophenoxy)-2-(phenyl- d 5 )acetic acid: An efficient 1 H NMR chiral solvating agent for direct enantiomeric purity evaluation of quinoline-containing antimalarial drugs Tetrahedron Asymmetry 2014 25 1605 1611 10.1016/j.tetasy.2014.11.007
32. Cavalluzzi M.M. Mangiatordi G.F. Nicolotti O. Lentini G. Ligand efficiency metrics in drug discovery: The pros and cons from a practical perspective Expert Opin. Drug Disc. 2017 12 1087 1104 10.1080/17460441.2017.1365056 28814111
33. Cavalluzzi M.M. Imbrici P. Gualdani R. Stefanachi A. Mangiatordi G.F. Lentini G. Nicolotti O. Human ether-a-go-go-related potassium channel: Exploring SAR to improve drug design Drug Discov. Today 2020 25 344 366 10.1016/j.drudis.2019.11.005 31756511
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.